Mark Jacobs, MD
Obstetrics & Gynecology · Houston, TXNPI 1073515201
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Therapeuticsmd, Inc. at 48.5% of the total. Reporting peaked in 2019 at $430 and has fallen 85.6% since, to $62 in 2025. That places this record below the midpoint for obstetrics & gynecology clinicians in TX, where the typical reported total is $863.
Across 31 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Therapeuticsmd, Inc.$314
- Pfizer$162
- Exact Sciences$40
- Amgen$32
- Avion Pharmaceuticals$28
- Astellas Pharma Global Development$22
- plus $49 from 3 others
Across 596 payments — averaging $4744.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exeltis, USA Inc.$950K
- Abbott$685K
- Sumitomo Pharma America, Inc.$667K
- Astellas Pharma Global Development$205K
- Ventana Medical Systems, Inc.$183K
- Myovant Sciences GmbH$73K
- plus $65K from 5 others
What the payments were for
- Food & beverage$61295%
- Education$173%
- Gifts$183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Therapeuticsmd, Inc. | 12 | $314 |
| Pfizer | 9 | $162 |
| Exact Sciences | 2 | $40 |
| Amgen | 2 | $32 |
| Avion Pharmaceuticals | 2 | $28 |
| Astellas Pharma Global Development | 1 | $22 |
| AbbVie | 1 | $18 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Agile Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIJUVA$111
How this compares
$647 in reported general payments places this provider in the 40th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 80 | $29,792 |
| PremproEstrogen,con/M-Progest Acet | 39 | $22,144 |
| Estradiol | 224 | $12,605 |
| DuaveeEstrogens,conj/Bazedoxifene | 13 | $6,694 |
| Estradiol (Twice Weekly)Estradiol | 28 | $3,126 |
| ElestrinEstradiol | 12 | $2,821 |
| YuvafemEstradiol | 14 | $2,724 |
| Raloxifene Hcl | 66 | $2,420 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 12 | $1,439 |
| ValacyclovirValacyclovir Hcl | 37 | $1,362 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $1,078 |
| ProgesteroneProgesterone, Micronized | 23 | $687 |
| Alendronate Sodium | 37 | $366 |
| Clobetasol Propionate | 17 | $337 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Prempro, Duavee | $162 | $58,629132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Houston
- George KuhnHouston$244K
- Daisy AyimHouston$188K
- Shannon WestinHouston$176K
- Asha BhalwalHouston$151K
- Nicole TranHouston$133K
- Sandra HurtadoHouston$123K
- Alvaro MontealegreHouston$92K
- Patti RossHouston$72K
- Damla KarsanHouston$58K
- Christopher JayneHouston$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.